Two of these (empagliflozin and dapagliflozin) are currently already repurposed in the treatment of the neutropenias present in GSD1b [3, 4, 14–17] and G6PC3-deficiency [4] and the third one (remogliflozin) was shown as being less specific for SGLT2 [24, 38]. The gene discussed is SLC5A2; the disease is Decreased total neutrophil count.